The FDA has green-lighted a new drug from Gilead Sciences as treatment for three types of blood cancer namely chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma and small lymphocytic lymphoma.
The FDA has green-lighted a new drug from Gilead Sciences as treatment for three types of blood cancer namely chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma and small lymphocytic lymphoma.